Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
PaperCitations, authors & open-access status
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 164 citations, 2018 year and closed oa status.
164
Citations
2018
Year
closed
OA Status